Brennan DE, Omorogbe J, Hussey M, Tighe D, Holleran G, O’Morain C, Smith SM, McNamara D. Molecular detection of Helicobacter pylori antibiotic resistance in stool vs biopsy samples. World J Gastroenterol 2016; 22(41): 9214-9221 [PMID: 27895408 DOI: 10.3748/wjg.v22.i41.9214]
Corresponding Author of This Article
Dr. Sinéad M Smith, PhD, Assistant Professor, Department of Clinical Medicine, School of Medicine, Trinity College Dublin, Tallaght, 2 Dublin, Ireland. smithsi@tcd.ie
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Prospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Nov 7, 2016; 22(41): 9214-9221 Published online Nov 7, 2016. doi: 10.3748/wjg.v22.i41.9214
Molecular detection of Helicobacter pylori antibiotic resistance in stool vs biopsy samples
Denise E Brennan, Joseph Omorogbe, Mary Hussey, Donal Tighe, Grainne Holleran, Colm O’Morain, Sinéad M Smith, Deirdre McNamara
Denise E Brennan, Joseph Omorogbe, Mary Hussey, Donal Tighe, Grainne Holleran, Colm O’Morain, Sinéad M Smith, Deirdre McNamara, Department of Clinical Medicine, School of Medicine, Trinity College Dublin, 2 Dublin, Ireland
Sinéad M Smith, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, 2 Dublin, Ireland
Author contributions: Smith SM and McNamara D contributed equally this work; Brennan DE, Omorogbe J, Hussey M, Tighe D, Holleran G, O’Morain C and McNamara D recruited patients and collected samples for the study; Brennan DE and Smith SM conducted experiments, analysed data and wrote the manuscript; all authors critically reviewed and approved the manuscript prior to publication.
Institutional review board statement: The study was reviewed and approved by the Adelaide and Meath Hospital Research Ethics Committee.
Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Sinéad M Smith, PhD, Assistant Professor, Department of Clinical Medicine, School of Medicine, Trinity College Dublin, Tallaght, 2 Dublin, Ireland. smithsi@tcd.ie
Telephone: +35-318-961385 Fax: +35-318-962988
Received: August 9, 2016 Peer-review started: August 11, 2016 First decision: September 12, 2016 Revised: September 27, 2016 Accepted: October 19, 2016 Article in press: October 19, 2016 Published online: November 7, 2016 Processing time: 88 Days and 17 Hours
Core Tip
Core tip: The successful detection of clarithromycin and/or fluoroquinolone resistant Helicobacter pylori (H. pylori) infections by non-invasive methods would enable a widespread assessment of resistance rates. Here we evaluate the GenoType HelicoDR assay for the detection of clarithromycin and fluoroquinolone resistance using DNA isolated from stool samples compared to biopsy samples. Although results using this assay on biopsy tissue have previously been shown to correspond well with culture and antimicrobial susceptibility testing, there was weak correlation between results obtained using biopsy vs stool samples in our study. Further studies are required to optimise the non-invasive detection of clarithromycin and fluoroquinolone resistant H. pylori infection.
